Dyee Capital
VC Fund
Xiamen, China
Dyee Capital is an investment firm.
- Total investments:
- 50
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Dyee Capital invests in
Stages Dyee Capital invests in
Countries Dyee Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dezhen Zhu
|
|||
|
Zhang Li
|
|||
Investment Focus
Industry
- Health Care 15 (30%)
- Biotechnology 15 (30%)
- Pharmaceutical 14 (28%)
- Medical 9 (18%)
- Biopharma 7 (14%)
Stage
- Series A 12 (24%)
- Series B 12 (24%)
- Series C 12 (24%)
- Series D 6 (12%)
- Venture - Series Unknown 4 (8%)
Country
- China 39 (78%)
- United States 4 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dezhen Zhu
Founder, Chairman and Managing Partner
|
Founder, Chairman and Managing Partner | Total investments: 0 | Find email | |
|
Zhang Li
executive director
|
executive director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GigaAI
|
Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space. | $147.9M / Series B / Jun 15, 2026 | |
|
Ningkasai Technology
|
Ningkasai Technology is a manufacturer of electronic components, specializing in the design, development, and production of high-performance parts that support a wide range of applications across the electronics and technology industries. | Series A / Oct 27, 2025 | |
Air white whale
|
Beluga Airlines is a large-scale unmanned cargo aircraft R&D and manufacturing company. | Series A / Jan 20, 2025 | |
Weikaier Pharmaceutical Technology
|
Weikaier Pharmaceutical provides R&D of innovative drugs, transfer of generic drug technology, the production and sales of pharmaceuticals. | $63.4M / Series C / Jan 02, 2024 | |
Huayuan Regenerative Medicine
|
Huayuan Regenerative Medicine is a developer of implantable biological artificial organs. | Seed / Nov 20, 2023 | |
Genepoint Biological Technology
|
Genepoint Biological Technology is a healthcare Company. | $29.6M / Series D / Jan 18, 2023 | |
ininin.com
|
ininin.com is an internet printing and design service platform. | Venture - Series Unknown / Nov 21, 2022 | |
Beijing Weilan New Energy Technology
|
Beijing Weilan New Energy Technology Co., Ltd. is a high-tech enterprise focusing on the development and production of next-generation all-solid-state batteries. One of the battery companies with patents and technologies for all solid-state battery cores. With the core concept of “Huijuwei Blue, Leading Solid State”, the company has a leadingdomestic and international leading technology and development team. | $208.8M / Series D / Nov 04, 2022 | |
BridGene Biosciences
|
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets. | $38.5M / Series B / Jul 27, 2022 | |
Degron Therapeutics
|
Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | $22M / Series A / Jun 09, 2022 | |
| See all 50 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dyee Capital invest in?
Dyee Capital invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 50 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dyee Capital?
Public channels for Dyee Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dyee Capital?
The team at Dyee Capital includes Dezhen Zhu (Founder, Chairman and Managing Partner) and Zhang Li (executive director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
